Inpatient antipsychotic drug use in 1998, 1993, and 1989

被引:88
作者
Centorrino, F
Eakin, M
Bahk, WM
Kelleher, JP
Goren, J
Salvatore, P
Egli, S
Baldessarini, RJ
机构
[1] McLean Hosp, Bipolar & Psychot Disorders Clin, Bipolar & Psychot Disoders Program, Belmont, MA 02478 USA
[2] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA
[4] Catholic Univ Korea, Coll Med, Dept Neuropsychiat, Seoul, South Korea
[5] Northeastern Univ, Bouve Coll Pharm & Allied Hlth Sci, Boston, MA 02115 USA
关键词
D O I
10.1176/appi.ajp.159.11.1932
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Patterns of clinical use of antipsychotic agents have changed greatly in the past decade. The authors' goal was to examine these patterns. Method: They evaluated medication use in all McLean Hospital inpatients treated with antipsychotic drugs during 3 months in 1998 (N=349) and compared the results with McLean Hospital inpatients treated with antipsychotics in 1993 (N=299) and Boston area inpatients in 1989 (N=50). Results: The most commonly prescribed antipsychotics in 1998 were atypical agents; olanzapine was prescribed more often than risperidone or quetiapine, which were prescribed more often than other antipsychotics. Two or more antipsychotics were prescribed at some time during their hospitalization for 150 (43%) of the patients in 1998. The total discharge dose in chlorpromazine equivalents for the 349 patients for whom antipsychotics were prescribed at discharge was 371 mg/day, 29% higher than the total discharge dose for patients in 1993 and 46%. greater than the dose in 1989. The dose of antipsychotics was greater for patients with psychotic illnesses than for those with affective illnesses. Higher doses were associated with greater clinical improvement, polypharmacotherapy, and younger patient age. Conclusions: Emerging trends toward higher total antipsychotic doses and polypharmacotherapy require critical assessments of cost-benefit relationships.
引用
收藏
页码:1932 / 1935
页数:4
相关论文
共 12 条
  • [1] BALDESSARINI RJ, 1984, AM J PSYCHIAT, V141, P748
  • [2] BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79
  • [3] BALDESSARINI RJ, 1995, AM J PSYCHIAT, V152, P1038
  • [4] Baldessarini RJ, 2001, GOODMAN GILMANS PHAR, P485, DOI DOI 10.1002/hup.540
  • [5] The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study
    Frye, MA
    Ketter, TA
    Leverich, GS
    Huggins, T
    Lantz, C
    Denicoff, KD
    Post, RM
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (01) : 9 - 15
  • [6] Hellewell JSE, 1999, J CLIN PSYCHIAT, V60, P14
  • [7] Pearsall R, 1998, PSYCHOPHARMACOL BULL, V34, P349
  • [8] Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution
    Procyshyn, RM
    Kennedy, NB
    Tse, G
    Thompson, B
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2001, 46 (04): : 334 - 339
  • [9] Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics
    Rittmannsberger, H
    Meise, U
    Schauflinger, K
    Horvath, E
    Donat, H
    Hinterhuber, H
    [J]. EUROPEAN PSYCHIATRY, 1999, 14 (01) : 33 - 40
  • [10] Antipsychotic polypharmacy, part 2: Tips on use and misuse
    Stahl, SM
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (08) : 506 - 507